Evidence-based framework for evaluating medical facilities offering Xeomin and Daxxify injections, including provider verification, product authenticity checks, and safety red flags.
Last reviewed: 2026-05-06
11 min read
Ready to explore your options in Istanbul?
Connect with our coordination team for a personalised treatment plan, verified provider matching, and travel logistics support.
Content is educational and planning-oriented. It does not replace diagnosis, treatment, or personalized medical advice from a licensed healthcare professional. Outcomes vary by individual case.
Both Xeomin and Daxxify are FDA-approved botulinum toxin products with distinct formulations that require proper facility handling and storage.
Facility audits should verify provider credentials, product source documentation, and adherence to cold-chain storage requirements.
The CDC warns against unlicensed providers and counterfeit products, which have caused serious adverse events requiring hospitalization.
Request product lot numbers, expiration dates, and provider licensing documentation before consenting to treatment.
International facilities should maintain protocols for adverse event escalation and coordinate with your home-care providers.
Educational information only
This content is general education and does not replace evaluation by a licensed clinician. If you have symptoms, complications, or urgent concerns, seek in-person medical care.
What Are Xeomin and Daxxify?
Xeomin (incobotulinumtoxinA) and Daxxify (daxibotulinumtoxinA) represent two distinct approaches to botulinum toxin type A formulations, each with characteristics that informed patients should understand when selecting a provider. Both products have received FDA approval and are used for cosmetic and therapeutic applications, though they differ significantly in their manufacturing processes, stabilizers, and duration profiles [S1, S3].
Xeomin, manufactured by Merz Pharmaceuticals, is derived from the same Hall strain of Clostridium botulinum as Botox but contains a key difference: it is free of complexing proteins. This purer formulation contains only 0.6 ng of clostridial proteins per 100-unit vial, which may reduce the risk of antibody formation in some patients [S1]. Xeomin uses a 1:1 unit conversion with Botox, meaning doses can be directly translated for patients switching between products [S1, S2]. The product is stored at room temperature (controlled environment, 20-25°C) before reconstitution, with a shelf life of 36-48 months, and after reconstitution should be kept at 2-8°C for no more than 24 hours to maintain sterility and efficacy [S1].
Daxxify, approved by the FDA on September 7, 2022, introduced a novel formulation approach using RTP004 peptide instead of human serum albumin as a stabilizer [S3, S4, S5]. This peptide-based technology contributes to Daxxify's notably longer duration of effect, with a median duration of 24 weeks (approximately 6 months) compared to the traditional 3-4 month duration of other botulinum toxins [S3, S4]. Phase 3 SAKURA clinical trials demonstrated that 74% of patients achieved at least a 2-point improvement at week 4, and some patients maintained results for up to 9 months in clinical studies [S3, S4]. Daxxify also demonstrates greater stability after reconstitution, remaining viable for up to 72 hours when stored at 2-8°C [S3].
The peptide stabilizer in Daxxify eliminates the need for human-derived proteins, which may reduce certain allergy-related concerns for patients sensitive to human serum albumin [S3]. However, as with any injectable treatment, patients should disclose their complete medical history, including any known allergies or sensitivities, to their provider before treatment.
Key Formulation Differences
Xeomin: Protein-free formulation, 1:1 Botox conversion, room temperature storage before reconstitution
Daxxify: Peptide-stabilized (RTP004), 6-month median duration, 72-hour post-reconstitution stability
The Centers for Disease Control and Prevention has documented increasing reports of harmful reactions from botulinum toxin injections, including difficulty swallowing and breathing, with some cases requiring hospitalization and antitoxin treatment [S6]. These adverse events frequently involve products purchased from unlicensed online sources, providers without valid healthcare licenses, or procedures performed in non-healthcare settings such as homes or unlicensed spas [S6].
When traveling internationally for these treatments, facility verification becomes especially important because medical facility standards vary by country. What constitutes proper accreditation in Turkey may differ from U.S. standards, and understanding these differences helps patients make informed decisions [S6]. The risks extend beyond immediate complications: counterfeit or mishandled products may not produce the expected duration of effect, leading to premature return of symptoms and potential need for repeat treatment sooner than anticipated.
A thorough facility audit protects patients from three categories of risk: product authenticity (ensuring the product is genuine FDA-approved medication and not counterfeit), provider competency (confirming the injector has appropriate training and licensing), and facility standards (verifying the clinical environment meets appropriate hygiene and safety requirements). Each of these elements contributes to treatment safety and outcomes.
Facility Audit Criteria
Evaluating a facility for Xeomin or Daxxify treatment requires examining multiple verification points before booking. The following criteria represent evidence-based standards that informed patients should confirm.
Provider Credentials and Training
Qualified injectors should hold current medical licenses appropriate to the procedures they perform. In Turkey, this typically includes certification from the Turkish Medical Association or equivalent regional medical boards. Beyond basic licensure, specialized training in facial anatomy and botulinum toxin injection technique significantly impacts outcomes and safety [S6]. Ask providers about their specific training history with Xeomin and Daxxify, including the number of procedures performed and any continuing education in toxin injection techniques.
When verifying provider credentials, request documentation of their medical license, any board certifications relevant to cosmetic injection procedures, and evidence of training specific to the products being used. A qualified provider should be transparent about their qualifications and willing to answer questions about their experience.
Product Source Authentication
Legitimate facilities maintain documentation of their product sourcing and can provide lot numbers, expiration dates, and manufacturer authenticity verification upon request. For Xeomin, confirm the product is sourced directly from Merz Pharmaceuticals or authorized distributors. For Daxxify, verify sourcing from Revance Therapeutics or approved channels [S1, S3]. Products should arrive in sealed, labeled vials with intact packaging—never accept product from unlabeled containers or questionable sources [S6].
Ask to see the product packaging before injection, and verify that the lot number matches facility documentation. Legitimate providers expect and welcome these verification questions from informed patients.
Storage and Handling Protocols
Proper cold-chain management is critical for botulinum toxin efficacy and safety. Xeomin should be stored at controlled room temperature (not exceeding 25°C) before reconstitution, while Daxxify requires refrigeration at 2-8°C until use [S1, S3]. After reconstitution with sterile saline, both products require refrigeration at 2-8°C, though Daxxify's 72-hour window is longer than the 24-hour window recommended for Xeomin [S1, S3]. Facilities should demonstrate temperature monitoring systems and documented storage logs for their toxin inventory.
Storage Warning Signs
Products stored at incorrect temperatures (ask to see storage logs)
Vials without clear lot numbers or expiration dates
Medical facilities offering injectable treatments should maintain appropriate clinical accreditation. Look for clean, dedicated treatment rooms with proper infection control protocols, appropriate emergency equipment availability, and documented waste disposal procedures. While specific accreditation requirements vary internationally, the presence of recognized medical facility certification provides baseline assurance of operational standards.
Browse verified facility options that meet international safety standards and maintain proper documentation for botulinum toxin administration.
Safety Red Flags and Warning Signs
Certain indicators should prompt immediate caution and potentially lead patients to seek alternative providers. The CDC specifically identifies several warning patterns associated with harmful botulinum toxin outcomes [S6].
Pricing red flags: Significantly below-market pricing may indicate counterfeit products, diluted formulations, or providers cutting corners on training and facility standards. Legitimate Xeomin and Daxxify treatments involve product costs that establish reasonable price floors.
Consultation red flags: Pressure tactics to book immediately without adequate consultation time, refusal to provide detailed product information, inability to answer questions about formulation differences, or reluctance to discuss potential risks and alternatives.
Facility red flags: Treatment performed outside of clean clinical environments, lack of appropriate medical supervision, providers unwilling to share their credentials or licensing information, and absence of emergency protocols or escalation procedures.
Product red flags: Vials that appear tampered, unlabeled containers, products lacking manufacturer packaging, or providers unwilling to show the product before injection [S6].
Your Patient Rights and Documentation
Patients have the right to receive complete information before consenting to any medical procedure. This includes understanding the specific product being used, its FDA approval status, expected duration, potential side effects, and what to do if complications arise.
Documentation You Should Receive
After treatment, request and retain the following documentation: the product lot number and expiration date, the exact injection sites and units delivered, the provider's name and credentials, the date of service, and written instructions for post-treatment care. This documentation is essential for coordinating follow-up care with providers in your home country and for reporting any adverse events to appropriate health authorities.
Contraindications and Pre-Treatment Considerations
Certain conditions contraindicate botulinum toxin treatment. Pregnancy and breastfeeding are absolute contraindications—you should not receive these treatments if you are pregnant, planning to become pregnant, or breastfeeding [S6]. Previous allergic reactions to botulinum toxin products also represent a contraindication requiring alternative approaches.
Discuss all medications and supplements with your provider before treatment. Blood-thinning medications, certain antibiotics, and muscle-relaxing medications may increase bruising risk or interact with botulinum toxin effects [S6]. Your complete medication history enables providers to assess risk factors and adjust treatment plans accordingly.
Adverse Event Protocols
Understand the facility's protocol for managing adverse events before booking. Serious complications, while rare, require prompt medical attention. Facilities should be able to provide emergency contact information and have clear escalation pathways. The CDC recommends reporting adverse events to FDA MedWatch and local health authorities to contribute to ongoing safety monitoring [S6].
Travel coordination support can help facilitate communication between your international provider and home-care clinicians for follow-up appointments and any concerns that arise after returning home.
When to Seek Immediate Care
Difficulty swallowing or breathing
Muscle weakness spreading beyond the injection site
Vision problems or drooping eyelids
Loss of bladder control
Signs of allergic reaction (rash, itching, swelling)
Action Steps for Safe Treatment
Taking a systematic approach to facility evaluation helps ensure safe, effective treatment outcomes.
Before your visit: Research facility credentials and reviews, confirm provider licensing and training, verify the facility uses FDA-approved products from authorized sources, and prepare a list of questions about storage, handling, and emergency protocols.
During your visit: Request to see product packaging before injection, confirm lot numbers match documentation, observe the treatment environment for cleanliness and organization, and ensure adequate consultation time with the provider.
After treatment: Document all details of the procedure, obtain complete post-care instructions with emergency contact information, retain all documentation for your medical records, and coordinate with home-care providers regarding your treatment.
Comparing Xeomin and Daxxify
Feature
Characteristic
Xeomin
Daxxify
Active Ingredient
IncobotulinumtoxinA
DaxibotulinumtoxinA
Stabilizer
None (protein-free)
RTP004 Peptide
FDA Approval
Multiple indications
Glabellar lines (2022)
Typical Duration
3-4 months
6 months (median)
Storage (unopened)
Room temperature 20-25°C
Refrigerated 2-8°C
Post-recon stability
24 hours at 2-8°C
72 hours at 2-8°C
Botox conversion
1:1
Separate dosing
Individual results vary with both products, and duration estimates represent median values rather than guarantees [S1, S3, S4]. Selecting between products depends on individual factors including treatment goals, previous response to botulinum toxins, and preference for duration versus other considerations. Consult with a qualified provider to determine which option best aligns with your specific needs.
Review your complete medical history with your provider, including any previous reactions to injectable treatments, current medications, and health conditions that may affect treatment. This information helps providers assess appropriateness for Xeomin or Daxxify and adjust dosing accordingly.
Arrange for travel coordination that includes post-treatment follow-up planning. Knowing how to reach your provider after returning home—and how to contact local emergency services if needed—ensures you have support throughout your recovery period.
External links are provided for educational reference. Verify guidance with qualified clinicians and primary sources where appropriate.
Ready to begin planning your medical travel journey? Our coordination team can assist with facility verification and provider background checks for international botulinum toxin treatments.
